Results 231 to 240 of about 105,778 (287)

Pancreas Transplantation Outcome Predictions-PTOP: A Risk Prediction Tool for Pancreas and Pancreas-Kidney Transplants Based on a European Cohort. [PDF]

Transplant Direct
Miller G, Ankerst DP, Kattan MW, Hüser N, Stocker F, Vogelaar S, van Bruchem M, Assfalg V.   +7 more
europepmc   +1 more source

Human intestinal and multivisceral transplantation [PDF]

, 1994
Abu-Elmagd, K, Cillo, U, Fung, JJ, Furukawa, H, Marino, IR, Scotti-Foglieni, CL, Starzl, TE, Todo, S, Tzakis, A   +8 more
core  

Cumulative exposure to tacrolimus is associated with increased risk of malignancy for solid organ transplant recipients

International Journal of Cancer, EarlyView.
What's New? Long‐term immunosuppression in solid organ transplant recipients (SOTRs) is linked to increased cancer risk. Although this risk potentially increases with greater immunosuppressant exposure, the exact dose‐response pattern remains uncertain.
Sergio A. Acuna, Xun Zhao, Maggie Jones‐Carr, Graham Smith, Kyla Naylor, Bima J. Hasjim, Shiyi Chen, An‐Wen Chan, Nancy Baxter, S. Joseph Kim, Mamatha Bhat   +10 more
wiley   +1 more source

Donor risk factors in pancreas transplantation. [PDF]

World J Transplant, 2020
Muñoz-Bellvís L, López-Sánchez J.
europepmc   +1 more source

Beyond a Conduit: The Evolution of Functional Biliary Stents From Active Intervention to Enabling Platforms

iNew Medicine, EarlyView.
This review traces the evolution of functional biliary stents, outlining the paradigm shift from “active intervention” strategies that target stent failure to next‐generation “enabling platforms.” These platforms leverage biodegradable materials, 3D/4D printing, and smart sensors to achieve personalized, regenerative, and theranostic solutions ...
Muhan Li, Xu Liu, Xin Ye, Zhixia Dong, Xinjian Wan   +4 more
wiley   +1 more source

Donor procurement for intestinal transplantation [PDF]

, 1997
Abu-Elmagd, K, Fung, JJ, Furukawa, H, Reyes, J, Starzl, TE, Todo, S   +5 more
core  

Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors

Interdisciplinary Medicine, EarlyView.
Napabucasin reduces liver metastases by reprogramming the hepatic microenvironment. It induces hepatocyte secretion of CCL21 via c‐Fos activation, recruiting lymphocytes and converting “cold” metastases into immunologically “hot” tumors. This effect is liver‐specific and independent of cancer cells.
Qiongqiong Wang, Jiaqi Zhou, Hang Qiao, Yifan Jia, Ling Ye, Zeli Li, Jiahe Ouyang, Haoxian Zhou, Kangxin Zeng, Xuemeng Wang, Yixian Wang, Yang Zhang, Yupeng Zhang, Yizhou Cai, Yutao Hu, Minzhe Zhang, Wenwei Xu, Zhenzhen Wu, Xiaofang Qiu, Li Lin   +19 more
wiley   +1 more source

Intestinal and multiple organ transplantation [PDF]

, 2005
Abu-Elmagd, K, Mazariegos, G, Reyes, J, Starzl, TE   +3 more
core